|
|
|
By BIO-IT World
 Forrester Research's senior healthcare analyst, Michael Barrett, is a highly regarded consultant on technology for clinical trials. Here, he shares some thoughts on electronic data capture with Mark Uehling.
Q: Some major companies claim all new trials are using EDC. Is this true?
A: If the firms had reframed their announcements and said, 'The new default position is that we do EDC — unless circumstances indicate otherwise,' they would have been right on the money. That's what they're really doing. They're saying, 'It's EDC, unless ...' That's a helluva lot different than their saying, 'It's paper, unless ...' That's a huge change.
Q: So EDC is here to stay?
A: Two-thirds of the top 12 companies are over the hump and have made the basic strategic decision to buy in. How they're going to implement it is another story. But make no mistake: The watershed moment has been reached.
Q: Why do you think large pharmaceutical companies are more innovative than small biotech companies?
A: Big Pharma has enough trials so that e-clinical solutions offer economies of scale. Big Pharma is leading the way in IT innovation. Small biotechs are just getting their toes into the water. They outsource trials because they have so few.
Q: How do contract research organizations fit into the story?
A: They feel the most threat. They deploy the warm bodies into the field, visiting doctors' offices every six weeks on behalf of drug firms. They aren't quite sure when they want to [reduce] those staffs and go electronic. The CROs are bruised and gun-shy at the very moment that Big Pharma is finally interested in moving. The CROs are now meshing their [EDC] worldview nicely with their smaller customers and losing credibility with their larger customers.
Q: What do you make of the FDA trying to clarify or renounce IT-related aspects of 21 CFR Part 11?
A: What we're seeing now are major public policy turnarounds focused explicitly on the FDA's not wishing to impede the adoption of technology in clinical trials. The FDA was persuaded by the parties it regulates that it had over-reached. You are seeing the ducks line up for the advance of clinical technology, whether it's clinical trials data capture or clinical care patient documents.
Q: Are the sponsors of clinical trials happy with the EDC vendor community?
A: Now, finally, Big Pharma believes in the solution and in many cases decides that the homegrown alternative is the best. That's kind of weird. IT — building and running IT solutions — isn't normally a Big Pharma core competency.
Q: So drug companies believe they can find drugs and write code?!
A: There are now power centers in these companies devoted to IT. These departments are fighting for their jobs. If they home-built a solution 10 years ago that's showing age, outsourcing it may not be appetizing. It may be threatening. The vendors have left themselves open to the [pharma] IT shops saying to their colleagues, 'Stick with us. We can do it.'
PHOTO OF MICHAEL BARRETT BY DANFURNESS/FAYFOTO
Back to Data Rapture?
|  Next-Generation Technologies Revolutionizing Oncology and Diagnostics
underwritten by Definiens
This “Briefing On” collection of Bio-IT World features, commentaries and analysis, presents some of the latest thinking on high-throughput technologies that are being applied to the fields of research and drug discovery, with particular emphasis on oncology, diagnostics and imaging technologies. Download now at no charge compliments of the underwriting sponsor, Definiens. Download This Free Paper
| |
This Bio•IT World Briefing On “Next-Generation Sequencing,” underwritten by GenomeQuest, Inc.,
presents a selection of feature stories, interviews,commentaries, conference reports, and editorials on the emergence, opportunities, and challenges posed by high-throughput sequencing. Covered in this collection: the launch of new platforms from Applied Biosystems and Helicos; new applications of nextgen sequencing; the rise of personal genomics; and informatics solutions to vexing problem of managing the vast volumes of next-gen data. Download now
| |  MetaMiner™ Cystic Fibrosis Report
Sponsored by GeneGo
This paper discusses the MetaMiner™ (CF) data analysis platform for a broad range of CF researchers designed to:
1. Easily assemble important biological and chemical experimental data available today in cystic fibrosis research.
2. Visualize key mechanisms leading to the disease through pathway maps and network models.
3. Provide the CF community a “one stop shop” tool for uploading and analyzing experimental data in a disease-centered interface.
Download Now
|
GenoLogics
Enabling Translational Research Informatics
Learn about the challenges facing life sciences research labs to manage their translational research data:
- The trends for organizations to adopt informatics solutions for translational research.
- The unique requirements with managing complex data and workflow.
- What labs should consider when reviewing informatics solutions for translational research.
- Which life sciences research organizations are successfully adopting an informatics solution.
Download Now
More Podcasts
Assistant Editor (Science Writer)~Cambridge Healthtech Institute (CHI), Needham, MA,
Cambridge Healthtech Institute seeks an assistant editor (science writer) who is an ambitious, dependable journalist who can fulfill a range of writing and editorial duties for a series of eNewsletters covering various aspects of the biopharmaceutical industry in addition to CHI’s flagship publication, Bio-IT World magazine. This is a superb opportunity to make important contributions to the growth and success of a multimedia science publishing group, while gaining invaluable experience in multiple facets of the publishing industry. Interested candidates should submit a cover letter, including 3 writing samples (attached in Word or PDF format), salary history or requirements, and resume to kdavies@healthtech.com. For a detailed description of the Assistant Editor position, please click here. Fred Hutchinson Cancer Research Center: IT Business Analyst III
The Hutchinson Center is the only National Cancer Institute-designated comprehensive cancer center in the Pacific Northwest. Through our Tumor Research Initiative, we are finding new ways to detect tumors at an early stage. We are presently seeking an experienced IT Business Analyst to assess technology needs for the Tumor Research Initiative, and to identify and design improvements to computer based systems. For more information please visit www.fhcrc.org and search for Job# AD-21465
|
|
|